Publications and Posters - Affimed

All categories

Publications

Posters

All Cell Engagers

acimtamig (AFM13)

AFM11

AFM24

AFM26

AFM28

Innate Cell Engager

All years

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

AFM13 in Patients with R/R Peripheral T cell Lymphoma (PTCL): A Post-hoc Subgroup Analysis From the REDIRECT Study

EHA 2023
Kim et al.

Leveraging innate immunity with AFM24, a novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager: Interim results for the non-small cell lung cancer (NSCLC) cohort

El-Khoueiry et al.
ASCO 2023

CD16A shedding facilitates repetitive targeting of tumor cells by AFM13-armed NK cells

Zambarda et al.
AACR 2023

Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated Relapsed or Refractory Peripheral T Cell Lymphoma at the American Association for Cancer Research Annual Meeting 2023

Kim et al.
AACR 2023

The Novel Bispecific Innate Cell Engager (ICE®) AFM28 Efficiently Directs Allogeneic NK Cells to CD123+ Leukemic Stem and Progenitor Cells in AML

Schmitt et al.
ASH 2022

AFM24 and atezolizumab combination in patients with advanced epidermal growth factor receptor-expressing (EGFR+) solid tumors: Initial results from the Phase 1 dose-escalation study

Saavedra et al.
SITC 2022

Targeting Epidermal Growth Factor Receptor (EGFR)-Expressing Solid Tumors With AFM24, A Novel CD16A Bispecific Innate Cell Engager: Comprehensive Correlative Science Findings From A Phase 1 Study

Hintzen et al.
SITC 2022

Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers

Pinto et al.
Trends in Immunology 43(11): 932-46.

link to publication

Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling

Hintzen et al.
Frontiers in Oncology. 2022 Sept 14

link to publication

A Phase 1/2a Dose Escalation Study of AFM24 in Patients With Epidermal Growth Factor Receptor-Expressing (EGFR) Solid Tumors: Results From Phase 1

Anthony El-Khoueiry et al.
ESMO 2022

1
2
3
4
5
6
7
8
9